Potential Therapy, CT1812, Seen as Safe and Able to Target Disease Markers, Cognition Reports

Potential Therapy, CT1812, Seen as Safe and Able to Target Disease Markers, Cognition Reports
Cognition Therapeutics’ lead drug candidate for mild-to-moderate Alzheimer’s disease (AD), CT1812, was shown to be well-tolerated and to lower brain levels of proteins involved in the disease, the company reports. These results, part of a Phase 1b/2a clinical trial, were given in an oral presentation at the recent 10th Clinical Trials on Alzheimer's Disease (CTAD) meeting in Boston by Lon Schneider, MD, a professor at the USC Keck School of Medicine,  and in a poster presentation by a company executive. An abstract on the Schneider's talk is titled “The Anti-Aβ Oligomer Drug CT1812 for Alzheimer’s: Phase 1b/2a Safety Trial Outcomes.” CT1812 is a small molecule that has shown an ability to effectively penetrate into the brain. Once there, it works to displace the amyloid-beta (Aβ) oligomers from their binding sites (or receptors) on neuron cells in the brain, and dispel the oligomers from the cerebrospinal fluid (CSF). Aβ oligomers are thought to play a major role in Alzheimer’s disease pathology, and CT1812 has demonstrated an ability to stop memory loss in animal models of AD. The clinical trial (NCT02907567) was conducted to determine the safety and pharmacokinetics (the drug's behavior in the body) of CT1812. It enrolled 19 people with mild-to-moderate AD, and treated them with either placebo or one of three doses of CT1812 (90, 280 and 560 mg) for 28 days. Levels of AD protei
Subscribe or to access all post and page content.

One comment

  1. william whitfield says:

    Speaking for the millions of my fellow sufferers and our loved ones who currently – barring an earlier demise – face without hope a lengthy, potentially decade or longer decline involving a horrific loss of mind and spirit before ultimately the body also dies, I have a few related questions I hope someone will be able and willing to answer.

    First, given the incredible >100 year history of Alzheimer’s dedicated medical researchers’ continuing failure to discover/develop even a single disease altering Alz treatment prior to this CT1812 potential one, just how long must even the currently defined ‘Fast Track’ designation still be required to run? Long enough for some (presumed) broadly applicable statistical measure of efficacy is met prior to allowing the currently doomed the same right to participate in a chance for life as have the trial participants? Or if so, shouldn’t this encouraging CT1812 development offer the community a chance to re-valuate existing ‘Fast Track’ criteria with a view towards identifying varying degrees of ‘fast track’ which can far better reflect any significantly varying circumstance or characteristic of a potential ‘fast track’ candidate?

    In any case, lacking an early major change to existing ‘Fast Track’ criteria by the FDA, certainly thousands and perhaps millions of us will continue to suffer and die without being afforded a chance to accept the same risks of failure or joys of success that roughly half of the selected trial participants will have.

    Finally, this also brings up the question of what if any laws have our legislatures enacted that gives our government (the FDA) the right to withhold from providers the ability to prescribe supervised access to almost any treatment or experimental drug that meets the existing requirements for an NIH approved trial participation? If none, shouldn’t there be, or to the extent such laws may exist, have they been challenged and found judicially to be in compliance with our Constitution?

    bw

Leave a Comment

Your email address will not be published. Required fields are marked *